Showing results (211-220 of 365) with videos related to

Sort By:
Pageof 37
Leukemia & Lymphoma|December 13, 2005
High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphomaSoo-Mee Bang, Yeo-Kyeoung Kim, Yeon Hee Park, et al.
Scientific Reports|June 25, 2016
Gene Expression Profiling of Breast Cancer Brain MetastasisJi Yun Lee, Kyunghee Park, Eunjin Lee, et al.
Cancer Research and Treatment|January 26, 2023
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER StudiesYong Wha Moon, Seung Ki Kim, Keun Seok Lee, et al.
Drug Safety|August 8, 2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelJoanne Wing Yan Chiu, Soo Chin Lee, James Chung-Man Ho, et al.
Cancer Research and Treatment|September 8, 2018
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of DiscordanceHee Kyung Kim, Kyung Hee Park, Youjin Kim, et al.
Breast Cancer Research and Treatment|October 17, 2018
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patientsHye Won Hwang, Hera Jung, Jiyeon Hyeon, et al.
Cancer Research and Treatment|December 19, 2015
The Effect of Intensified Induction Using Vanderbilt Regimen in Patients with an Intermediate Grade Non-Hodgkin's Lymphoma Having 2 or 3 Adverse Factors on the Age-adjusted International Prognostic IndexYoong Ju Kweon, Seong Jun Choi, Baek Yeol Ryoo, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.
Cancers|July 14, 2023
Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort StudyYoungji Kwak, Sung Yoon Jang, Joon Young Choi, et al.
BMC Cancer|October 6, 2010
Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeSeong Yoon Yi, Jin Seok Ahn, Ji Eun Uhm, et al.
Pageof 37